PapersFlow Research Brief
Rheumatoid Arthritis Research and Therapies
Research Guide
What is Rheumatoid Arthritis Research and Therapies?
Rheumatoid arthritis research and therapies encompass the scientific investigation of diagnostic classification criteria, disease activity assessment tools, pathogenic mechanisms, and pharmacological management strategies for rheumatoid arthritis, a chronic autoimmune disorder characterized by synovial inflammation and joint destruction.
Rheumatoid arthritis research includes over 113,652 published works focused on classification criteria, disease activity scores, and treatment guidelines. Arnett et al. (1988) introduced revised criteria for RA classification based on analysis of 262 RA patients and 262 controls, emphasizing morning stiffness, arthritis of three joint areas, and rheumatoid nodules. Aletaha et al. (2010) developed updated ACR/EULAR criteria to improve sensitivity for early disease detection.
Research Sub-Topics
Rheumatoid Arthritis Classification Criteria
ACR/EULAR 2010 criteria and predecessors standardize RA diagnosis for research using joint counts, serology, and acute phase reactants. Researchers validate criteria performance across populations and early disease stages.
Disease Activity Assessment in RA
DAS28, CDAI, and SDAI composite scores monitor treatment response using tender/swollen joints, patient global assessment, and CRP/ESR. Researchers develop simplified indices and validate cutoffs for remission.
Pathogenesis of Rheumatoid Arthritis
Autoimmune mechanisms involving citrullinated peptides, PTPN22, and synovial inflammation leading to joint destruction. Researchers elucidate genetic, epigenetic, and environmental triggers through omics approaches.
Biologic DMARDs in Rheumatoid Arthritis
TNF inhibitors, IL-6 blockers, B-cell depletion, and T-cell costimulation modulators for moderate-severe RA. Researchers compare efficacy, safety, biosimilars, and sequencing in real-world cohorts.
EULAR RA Management Recommendations
Evidence-based guidelines for synthetic and biologic DMARDs emphasizing methotrexate first-line and treat-to-target. Researchers update recommendations through systematic reviews and Delphi consensus.
Why It Matters
Rheumatoid arthritis research and therapies enable standardized diagnosis and treatment, impacting clinical practice across rheumatology. The 1987 revised criteria by Arnett et al. (1988) with 19,773 citations provide a foundation for identifying RA in 262 studied patients, facilitating consistent patient enrollment in trials. EULAR recommendations by Smolen et al. (2017) guide use of synthetic and biological DMARDs, while McInnes and Schett (2011) detail pathogenesis leading to therapies that alter disease course and reduce mortality. Recent trials like the RESET-RA vagus nerve modulation study (2025) and bioengineered nanothylakoids (2025) target inflammatory microenvironments, addressing treatment-refractory cases as shown in spatial transcriptomics studies of fibroblasts (2026).
Reading Guide
Where to Start
"The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis" by Arnett et al. (1988) provides the foundational diagnostic framework through analysis of 262 patients and controls, essential for understanding RA classification basics.
Key Papers Explained
Arnett et al. (1988) established baseline RA criteria, revised by Aletaha et al. (2010) for early disease sensitivity via ACR/EULAR collaboration. Prevoo et al. (1995) built on these with DAS28 validation for activity monitoring, while Smolen et al. (2017) integrated criteria into EULAR management guidelines for DMARDs. McInnes and Schett (2011) linked pathogenesis to therapeutic advances across these works.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints explore fibroblast remodeling in treatment-refractory RA via spatial transcriptomics (2026), AI/single-cell methods for autoimmune insights (2025), and pathological mechanisms with meta-analysis of treatments (2026). News highlights vagus nerve trials (RESET-RA, 2025), nanothylakoid therapies (2025), and single-cell RNA-seq datasets for TNF/JAK inhibitors (2025).
Papers at a Glance
In the News
Bioengineered photosynthetic nanothylakoids reshape the inflammatory microenvironment for rheumatoid arthritis therapy
* Published:05 December 2025# Bioengineered photosynthetic nanothylakoids reshape the inflammatory microenvironment for rheumatoid arthritis therapy
Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial
RESET-RA trial.
Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF/JAK inhibitor treatment
drug-specific treatment outcomes in RA.
A single-cell RNA-seq dataset of synovial fluid from rheumatoid arthritis treated with TNF-α/JAK inhibitor
functional characteristics. This dataset offers a valuable resource for addressing a range of research questions, including elucidating the mechanisms of action of tofacitinib and adalimumab, ident...
Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
# Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
Code & Tools
Feedback and issues about this empty framework can be submitted via the issues page, and will be incorporated into subsequent releases. The Core Ar...
The BpresenT framework consists of multiple flexible Python modules encapsulated in a Django project. It incorporates two publicly available tools:...
`iviRA`is an R package that runs the Innovation and Value Initiative's (IVI's) individual patient simulation model for rheumatoid arthritis (RA) (t...
Ensmeble DRP is Ensemble Learning for Drug Response Prediction with its primary aim to use ensemble machine learning methods to predict patients's ...
**Type:**Health Service Modelling Associates (HSMA4) project **Title:**"The role of Patient Initiated Follow-Up and 'Digital Outpatients' in suppor...
Recent Preprints
Exploring Pathological Mechanisms and the Impact ...
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation and progressive joint destruction. This study aims to explore the intricate pathological...
The Journal of Rheumatology
Loading * What Is Allopurinol Failure and What Should We Do About It? * Autoinflammatory Diseases: A Review * Rheumatoid Arthritis: The Continuum of Disease and Strategies for Prediction, Early ...
Using Novel AI and Single-Cell Techniques to Advance ...
Topics: Research , Rheumatoid Arthritis , Autoimmune disease , Artificial Intelligence (AI) Spread the word: Featured Experts Fan Zhang, PhD ## Related Articles ### What is Teplizumab? Why...
Scientists discover natural 'brake' that could stop harmful ...
The discovery opens the door to clinical trials exploring sEH inhibitors as potential therapies for conditions like rheumatoid arthritis and cardiovascular disease. Dr Bracken said: "For instance, ...
Fibroblasts determine treatment outcome in rheumatoid arthritis
Treatment-refractory rheumatoid arthritis is a major unmet clinical need, and the mechanisms that underlie resistance to therapy remain poorly understood. Using high-resolution spatial transcriptom...
Latest Developments
Recent developments in rheumatoid arthritis research include the identification of an alternative inflammatory pathway that could lead to improved treatments (WSU), the approval of the FDA-approved implantable vagus nerve device SetPoint System in July 2025, which offers a potential cure (Northwell Health), and ongoing studies of new biologic therapies such as olokizumab and bispecific T cell engager therapy showing promising results (NEJM, Nature Medicine). Additionally, research continues into novel drugs like upadacitinib, which has demonstrated efficacy and safety over five years (JRheum, Arthritis Research & Therapy).
Sources
Frequently Asked Questions
What are the 1987 revised criteria for RA classification?
The 1987 American Rheumatism Association criteria, developed by Arnett et al. (1988), were formulated from 262 RA patients and 262 controls, requiring morning stiffness, arthritis in three joint areas, hand involvement, symmetric arthritis, and rheumatoid nodules for classification. These criteria achieved high specificity for established disease. They remain a benchmark despite updates for early RA.
How do the 2010 ACR/EULAR criteria improve on prior versions?
Aletaha et al. (2010) created new criteria addressing 1987 limitations in early disease sensitivity through a collaborative initiative scoring joint involvement, serology, acute-phase reactants, and duration. A score of 6/10 or more classifies RA. These criteria enhance early detection vital for timely therapy.
What is the role of DAS28 in RA management?
Prevoo et al. (1995) validated modified disease activity scores using 28-joint counts (DAS28), equivalent to fuller joint assessments in prospective RA studies. DAS28 incorporates tender/swollen joint counts, ESR/CRP, and patient global assessment. It supports treatment decisions on DMARD efficacy.
What do EULAR recommendations cover for RA?
Smolen et al. (2017) updated EULAR guidelines for managing RA with synthetic and biological DMARDs, emphasizing treat-to-target strategies. Recommendations prioritize methotrexate and escalate to biologics based on response. They integrate evidence up to 2016 for optimized outcomes.
What pathogenic insights drive RA therapies?
McInnes and Schett (2011) outlined RA pathogenesis involving immune mechanisms like synovial inflammation, leading to therapies altering disease history and reducing mortality. Key processes include cytokine-driven joint destruction. This understanding supports targeted biologics like TNF inhibitors.
Open Research Questions
- ? How can spatial transcriptomics identify mechanisms of fibroblast-driven treatment resistance in RA as noted in recent preprints?
- ? What neuroimmune pathways underlie vagus nerve modulation efficacy in the RESET-RA trial for RA?
- ? Which single-cell profiles predict drug-specific outcomes for TNF/JAK inhibitors in RA synovial fluid?
- ? How do bioengineered nanothylakoids reshape inflammatory microenvironments to improve RA therapy?
- ? What AI and single-cell techniques best advance RA autoimmune mechanism discovery?
Recent Trends
Field growth reached 113,652 works, with preprints emphasizing single-cell analysis of synovial fluid under TNF/JAK inhibitors , fibroblast roles in therapy failure via spatial transcriptomics (2026), and vagus nerve modulation in RESET-RA trial (2025).
2025Nanothylakoid reshaping of inflammation and AI/single-cell advancements (2025) mark shifts toward precision interventions.
2025Research Rheumatoid Arthritis Research and Therapies with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Rheumatoid Arthritis Research and Therapies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.